Propofol Injection, Emulsion
NDC Package 0409-4699-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Propofol injection is propofol injectable emulsion is an IV general anesthetic and sedation drug that can be used as described in the table below. This formulation utilizes a injection, emulsion delivery system. Marketed by Hospira, Inc., this product is identified by NDC 0409-4699 and is authorized under FDA application ANDA077908.

Identification & Billing

NDC Package Code
0409-4699-30
Package Description
5 VIAL in 1 CARTON / 20 mL in 1 VIAL (0409-4699-50)
Product Code
11-Digit Billing Format
00409469930
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Propofol
Non-Proprietary Name
Propofol
Substance Name
Propofol
Dosage Form
Injection, Emulsion - An emulsion consisting of a sterile, pyrogen-free preparation intended to be administered parenterally.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Usage Information
Propofol injectable emulsion is an IV general anesthetic and sedation drug that can be used as described in the table below. TABLE 3. INDICATIONS FOR PROPOFOL INJECTABLE EMULSIONIndicationApproved Patient PopulationInitiation and maintenance of Monitored Anesthesia Care (MAC) sedation Adults onlyCombined sedation and regional anesthesia Adults only (see PRECAUTIONS)Induction of General Anesthesia Patients greater than or equal to 3 years of ageMaintenance of General Anesthesia Patients greater than or equal to 2 months of ageIntensive Care Unit (ICU) sedation of intubated, mechanically ventilated patients Adults onlySafety, effectiveness and dosing guidelines for propofol injectable emulsion have not been established for MAC Sedation in the pediatric population; therefore, it is not recommended for this use (see PRECAUTIONS, Pediatric Use). Propofol injectable emulsion is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations. In the Intensive Care Unit (ICU), propofol injectable emulsion can be administered to intubated, mechanically ventilated adult patients to provide continuous sedation and control of stress responses only by persons skilled in the medical management of critically ill patients and trained in cardiovascular resuscitation and airway management. Propofol injectable emulsion is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established (see PRECAUTIONS, Pediatric Use). Propofol injectable emulsion is not recommended for obstetrics, including Cesarean section deliveries. Propofol injectable emulsion crosses the placenta, and as with other general anesthetic agents, the administration of propofol injectable emulsion may be associated with neonatal depression (see PRECAUTIONS). Propofol is not recommended for use in nursing mothers because propofol injectable emulsion has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of propofol are not known (see PRECAUTIONS).

Regulatory & Marketing

Labeler Name
Hospira, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA077908
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-03-2006
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Source: PDAC
UNCLASSIFIED DRUGS
HCPCS Dosage 1 EA
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0409-4699). Click a package code to view its specific billing and regulatory data.

10 VIAL in 1 TRAY / 100 mL in 1 VIAL (0409-4699-54)
20 VIAL in 1 TRAY / 50 mL in 1 VIAL (0409-4699-53)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0409-4699-30 identifies a specific commercial package of 5 vial in 1 carton / 20 ml in 1 vial (0409-4699-50) of Propofol, a human prescription drug labeled by Hospira, Inc.. This injection, emulsion is formulated for intravenous use and contains propofol as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hospira, Inc. on April 03, 2006. The current certification is valid through December 31, 2026.

How is this Hospira, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00409469930. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0409-4699-30
11-Digit CMS (5-4-2)
00409-4699-30

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.